Clinical trial
Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer
NCT00496756 · University of Nebraska, Other · Terminated
Key facts
| NCT number | NCT00496756 |
|---|---|
| Title | Sorafenib in Treating Patients With Metastatic or Unresectable Kidney Cancer |
| Official title | A Phase II Study of Sorafenib in Patients With Metastatic Renal Cell Carcinoma |
| Lead sponsor | University of Nebraska, Other |
| Collaborators | National Cancer Institute (NCI) NIH Bayer Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Kidney Cancer |
| Intervention type | Drug |
| Interventions | Sorafenib |
| Enrollment | 14 |
| Start date | Mar 1, 2007 |
| Primary completion | Oct 31, 2009 |
| Completion | Apr 25, 2014 |
| First posted | Jul 4, 2007 |
| Last update posted | Oct 26, 2023 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: